- Home
- LIVN vs TARS Comparison
LIVN vs TARS Comparison
Compare LIVN & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIVN
- TARS
- Stock Information
- Founded
- LIVN 1987
- TARS 2016
- Country
- LIVN United Kingdom
- TARS United States
- Employees
- LIVN N/A
- TARS N/A
- Industry
- LIVN Biotechnology: Electromedical & Electrotherapeutic Apparatus
- TARS Medicinal Chemicals and Botanical Products
- Sector
- LIVN Health Care
- TARS Health Care
- Exchange
- LIVN Nasdaq
- TARS Nasdaq
- Market Cap
- LIVN 2.1B
- TARS 1.7B
- IPO Year
- LIVN 1993
- TARS 2020
- Fundamental
- Price
- LIVN $55.45
- TARS $57.88
- Analyst Decision
- LIVN Strong Buy
- TARS Strong Buy
- Analyst Count
- LIVN 7
- TARS 7
- Target Price
- LIVN $59.71
- TARS $67.14
- AVG Volume (30 Days)
- LIVN 774.7K
- TARS 689.6K
- Earning Date
- LIVN 08-06-2025
- TARS 08-06-2025
- Dividend Yield
- LIVN N/A
- TARS N/A
- EPS Growth
- LIVN N/A
- TARS N/A
- EPS
- LIVN N/A
- TARS N/A
- Revenue
- LIVN $1,309,329,000.00
- TARS $295,521,000.00
- Revenue This Year
- LIVN $11.29
- TARS $33,170.29
- Revenue Next Year
- LIVN $6.59
- TARS N/A
- P/E Ratio
- LIVN N/A
- TARS N/A
- Revenue Growth
- LIVN 8.23
- TARS 254.45
- 52 Week Low
- LIVN $32.48
- TARS $25.82
- 52 Week High
- LIVN $57.35
- TARS $58.95
- Technical
- Relative Strength Index (RSI)
- LIVN 76.87
- TARS 74.75
- Support Level
- LIVN $54.50
- TARS $56.04
- Resistance Level
- LIVN $56.70
- TARS $58.95
- Average True Range (ATR)
- LIVN 1.39
- TARS 1.95
- MACD
- LIVN 0.39
- TARS 0.41
- Stochastic Oscillator
- LIVN 93.11
- TARS 90.89
About LIVN LivaNova PLC
UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.